http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100197792-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bbb7e0584e2cd03abf527efa781deff2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-54 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 |
| filingDate | 1996-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1999-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16f0708149e2b9a9b5bad7271ae4f081 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2fdf64953ba4e4b8df23bcb9fb0e9ae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_672ada4aa923e5fa41ee11ea2a8e9056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48d47fadacfda0252a10382b59544e2e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d826f5dccab0690db6971f80349895e1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdb61642bcf2e1aaf2d66599a0e0ba28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1854f564d606507445cf474bcb4e829c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3020e45d7b5f4d746dad59de0ac8f9c9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c56eeb25d69c13acc63a3fc5d20e0710 |
| publicationDate | 1999-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100197792-B1 |
| titleOfInvention | New antiviral 2-bis (hydroxymethyl) cyclopropane-1-methylpyrimidinedione derivatives and methods for their preparation |
| abstract | The present invention relates to 2-bis (hydroxymethyl) cyclopropane-1-methylpyrimidinedione derivatives as shown by general formula (I) which are useful as antiviral agents, especially for the treatment of acquired immunodeficiency syndrome (AIDS) Possible salts. The invention also relates to a process for preparing such compounds and to pharmaceutical compositions containing such compounds as active ingredients.n n n n n n n n In the above general structural formula (I) R 1 is a hydrogen atom, a halogen atom, C 1 -C 10 alkyl, C 1 -C 10 alkyl group in the thio, C 3 cyclic substituted or unsubstituted alkyl group of -C 8, C 1 - selenium alkyl substituent of C 10, alkyl amine group of C 1 -C 10 alkoxy group, C 1 C 10 alkoxy group, C 1 -C 10 of a, R 2, R 3 are each independently a hydrogen atom, a halogen atom , A C 1 -C 10 alkyl group, a C 1 -C 10 thioalkyl group, a C 1 -C 10 alkoxy group, a C 1 -C 10 thioalkoxy group, a C 1 -C 10 alkylamine group, and R 4 , and R 5 are each a hydrogen atom, and as a protecting group, a benzyl group, a substituted carbonyl group, a substituted sulfonyl group, a substituted silane group, and the like. Z represents a hydrogen atom, a sulfur atom, a carbon atom or a carbonyl group, X is an oxygen atom, a sulfur atom, and n is an integer of 1-3. |
| priorityDate | 1996-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 84.